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We used metabolic, enzymatic, and functional end points to compare the 
protective properties of continuous warm and intermittent cold cardiople- 
gic infusion in isolated, blood-perfused rat hearts. After excision, hearts 
(n = 12 per group) were preserved for 3 hours by one of the following 
cardioplegic procedures: (1) continuous infusion of warm (37 ° C) blood 
cardioplegic solution prepared by mixing Fremes' solution with rat arterial  
blood in a ratio of 1:4, (2) continuous infusion of warm (37 ° C) crystalloid 
cardioplegic solution prepared by mixing Fremes' solution with bicarbonate 
buffer solution in a ratio of 1:4, or (3) intermittent infusion of cold (20 ° C) 
St. Thomas' Hospital cardioplegic solution number 2 infused for 3 minutes 
every 30 minutes during a 3-hour period of ischemia. In the continuous- 
infusion cardioplegic groups, the solution was infused through the aorta at 
a flow rate of 0.8 ml .min  - l .gm -1 heart. At the end of the 3-hour 
preservation period, myocardial sodium-potassium adenosine triphos- 
phatase activity (an index of ion-exchange activity) was assessed in six 
hearts in each group. The remaining hearts in each group were then 
aerobically perfused at 37 ° C with arterial  blood (from a support rat) for a 
further 50 minutes, during which time they were atrial ly paced at 320 
beats/min. At the end of this period, left ventricular developed and 
end-diastolic pressures were assessed with an intraventricular balloon; the 
hearts were then freeze-clamped and taken for the measurement of tissue 
adenosine tr iphosphate and creatine phosphate content. Hearts (n = 6) 
aerobically perfused with blood for 50 minutes (no cardioplegic infusion) 
served as control preparations. At a balloon volume of 180 ptl, the mean 
final values for left ventricular developed pressure in the continuous warm 
blood, continuous warm crystalloid, and intermittent cold cardioplegic 
groups were 98 +- 5 mm Hg (p < 0.05), 70 - 5 mm Hg, and 78 -+ 5 mm Hg, 
respectively. This was compared with 122 - 5 mm Hg in control hearts (p < 
0.05 vs the rest). For left ventricular end-diastolic pressure, the correspond- 
ing values were 33 -+ 3 mm Hg, 32 -+ 6 mm Hg, and 14 - 4 mm Hg (p < 
0.05), respectively. The control value was 16 - 3 mm Hg (p < 0.05 vs 
continuous warm blood and continuous warm crystalloid groups). Tissue 
content of adenosine tr iphosphate was similarly reduced to approximately 
50% of control values in all groups, and creatine phosphate content fully 
recovered in all groups. Sodium-potassium adenosine tr iphosphatase ac- 
tivity was poorly preserved in continuous warm crystal loid-treated hearts 
(0.012 +- 0.003 vs 0.030 - 0.008/_tmol inorganic phosphate,  mg -a .  min -1 
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in control preparations, p < 0.05), whereas in continuous warm blood and 
intermittent cold cardioplegic groups (0.032 -+ 0.015 and 0.031 - 0.013 
gmol inorganic phosphate, mg -1- min -1) there was no significant loss of 
activity. In conclusion, (1) none of the procedures conferred complete 
protection, (2) continuous warm blood cardioplegic infusion provided 
superior preservation of systolic function and intermittent cold cardiople- 
gic infusion afforded superior protection with respect to diastolic function, 
and (3) both continuous warm blood and intermittent cold cardioplegic 
infusion similarly protected sodium-potassium adenosine triphosphatase 
activity and tissue adenosine triphosphate and creatine phosphate content, 
whereas continuous warm crystalloid cardioplegic infusion afforded poor 
preservation of sodium-potassium adenosine triphosphatase activity. In 
general, the poorest protection was afforded by continuous warm crystalloid 
cardioplegic infusion. (J Thorac Cardiovasc Surg 1996;112:797-805) 
ardiac pump failure is the main cause of morbidity 
and mortality during heart operations. A full un- 
derstanding of the mechanisms that precipitate this 
surgically induced heart failure and the consequent 
development of protective interventions to prevent it 
are of great importance if we are to improve survival 
and safety during cardiac operations. Intermittent cold 
cardioplegic infusion with ischemic arrest is the 
method most widely employed for protection during 
cardiac operations, and although it generally affords 
satisfactory esults, there are still a significant number 
of patients for whom standard protection appears to 
be insufficient, either because of an initial impairment 
of cardiac contractile function or because of a long 
period of ischemia required for the surgical correction. 
The myocardial protection obtained with intermittent 
cold cardioplegic infusion is based on the following 
principles: (1) the induction and maintenance ofrapid 
cardiac arrest during the ischemic period, (2) the 
reduction of detrimental metabolic processes by the 
use of hypothermia, nd (3) the intermittent washout 
of toxic metabolites by multiple infusions of the car- 
dioplegic solution. 1It has been argued, however, that 
ischemic injury will still occur with this form of protec- 
tion and that hypothermia itself may cause cellular 
damage. It has been suggested that hypothermia may 
cause decreased fluidity of cell membranes, which may 
impair transport functions, 2 inactivation of sodium- 
potassium adenosine triphosphatase (Na+/K +- 
ATPase) and calcium ion adenosine triphosphatase 
(ATPase) of the sarcoplasmic reticulum, leading to 
calcium overload and a loss of cell volume control, 3' 4 
and denaturation of key proteins. 5 
It has recently been suggested that continuous 
warm cardioplegic infusion, which eliminates the 
need for ischemia nd hypothermia, may be a better 
form of protection. 6,v It has been argued that 
electromechanical arrest under normothermic con- 
ditions (which allows reduction of oxygen consump- 
tion by 90%) reduces energy demand sufficiently to 
allow coronary flow to be safely reduced to values 
much lower than those required under physiologic 
conditions. This reduction would facilitate the sur- 
gical correction without risking ischemic injury. 
Early clinical studies have suggested that continuous 
warm cardioplegic infusion is an effective protective 
procedure,6, 7 although a greater prevalence of neu- 
rologic problems has been reported. 8 Data from 
controlled experimental studies comparing the pro- 
tective power of continuous warm versus intermit- 
tent cold cardioplegic infusion, however, have not 
been reported. 
Potential complications that can arise from the 
use of continuous blood cardioplegic infusion in- 
clude embolization of microaggregates and constant 
exposure of the coronary vasculature to activated 
neutrophils. It may therefore be hypothesized that 
the continuous infusion of a crystalloid asanguine- 
ous solution could be a safer alternative. The aims of 
this study were therefore to do the following: (1) 
compare the myocardial protection afforded by con- 
tinuous infusion of warm cardioplegic solution with 
that afforded by intermittent infusion of cold car- 
dioplegic solution and (2) investigate the impor- 
tance of the presence of blood elements in the 
protective properties of continuous warm cardiople- 
gic infusion. To achieve this end, we employed the 
isolated, blood-perfused rat heart to examine the 
recovery of systolic and diastolic cardiac function, 
tissue high-energy phosphate content, and myocar- 
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Table I. Composition of  cardioplegic solutions 
Blood Crystalloid St. Thomas' 
cardioplegia cardioplegia cardioplegic solution 
(retool~L) (retool~L) number 2 (mmol/L ) 
Sodium ion 104.4 95.0 120.0 
Potassium ion 10.3 9.6 16.0 
Calcium ion 1.0 1.1 1.2 
Magnesium ion 2.8 2.8 16.0 
Bicarbonate ion 16.8 20.0 10.0 
Tris(hydroxymethyl)aminomethane 12.0 12.0 0 
Glucose 59.0 58.9 0 
pH 7.4 7.4 7.8 
Hematocrit (%) 17.8 0 0 
dial Na+/K+-ATPase  activity as end points of injury 
and protect ion. 
Materials and methods 
Animals. Adult male rats of the Wistar strain were 
used. All animals received humane care in compliance 
with the "Principles of Laboratory Animal Care" formu- 
lated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Blood-perfused heart preparation. The blood-per- 
fused, isolated rat heart preparation and techniques are 
described elsewhere in detail. 9
Support rats. The rats (300 to 350 gm body weight) were 
anesthetized with 60 mg/kg intraperitoneal pentobarbital 
and placed supine on a heated pad (37.0 +- 0.5 ° C). The 
animals were allowed to spontaneously breathe a mixture 
of humidified 95% oxygen plus 5% carbon dioxide, with 
the flow rate controlled to maintain arterial oxygen and 
carbon dioxide tensions within physiologic ranges. Hepa- 
rin was administered intravenously at 1000 IU/kg, and a 
femoral artery and vein were cannulated to provide an 
arterial blood supply to the donor heart and to allow the 
return of blood to the support animal. The extracorporeal 
circuit was primed with 5 ml plasma substitute (Haemac- 
cel; Hoechst UK Ltd., Behring Diagnostics Div., Mid- 
dlesex, U.K.) mixed with 2 ml 0.9% saline solution plus 5 
ml blood (obtained from a donor rat). In this way, the 
plasma ions, blood gas values, and pH of the support rat 
were maintained within physiologic ranges. Only the levels 
of hemoglobin and the hematocrit were slightly reduced 
as a consequence of hemodilution (falling to between 10 
and 12 gm/dl and 30% and 36%, respectively). Arterial 
blood pressure and heart rate were continuously recorded. 
Isolated hearts. Donor rats (220 to 280 gm body weight) 
were anesthetized with diethyl ether and given 1000 IU/kg 
heparin intravenously. Thirty seconds later, the heart was 
excised and the aorta was cannulated. Blood or crystalloid 
cardioplegic solution was then infused, and hearts were 
stored according to the desired protocol. At the end of 3 
hours of storage, hearts were perfused for another 50 
minutes in the Langendorff mode with arterial blood from 
a support rat at a constant flow of 2.5 ml/min. Blood was 
delivered to the isolated heart by means of a roller pump 
(Minipuls 3; Gilson, Villers-le-Bel, France), and the mean 
coronary perfusion pressure was continuously monitored 
by means of a pressure transducer connected to the aortic 
cannula. At the end of the experiment, cardiac systolic and 
diastolic function were assessed by means of an intraven- 
tricular balloon catheter that was introduced into the left 
ventricle through the left atrium. Pressure-volume curves 
were constructed by stepwise increases in balloon volumes 
(30, 60, 90, 120, 150, 180, 210, and 240/xl). 
Preparation and administration of cardioplegie solu- 
tions. Blood cardioplegic solution was prepared by mixing 
Fremes' solution (containing 30 mmol/L potassium chlo- 
ride, 9 mmol/L magnesium sulfate, 12 mmol/L tris(hy- 
droxymethyl)aminomethane, 250 mmol/L glucose, and 20 
ml/L citrate-phosphate-dextrose solution) with rat arterial 
blood in a ratio of 1:4. Arterial blood was obtained from 
six to seven anesthetized donor rats through a catheter 
inserted into the abdominal aorta. Warm crystalloid car- 
dioplegic solution was prepared by mixing Fremes' solu- 
tion with oxygenated bicarbonate buffer (containing 11.1 
mmol/L glucose, 118.5 mmol sodium chloride, 4.8 mmol/L 
potassium chloride, 1.2 mmol/L magnesium sulfate, 1.2 
mmol/L monobasic potassium phosphate, 25.0 mmol/L 
sodium bicarbonate, and 1.4 mmol/L calcium chloride) in 
a ratio of 1:4. St. Thomas' Hospital cardioplegic solution 
number 2 was used for intermittent cold cardioplegia. The 
final compositions of the cardioplegic solutions used are 
shown in Table I. 
In hearts protected with continuous cardioplegic infu- 
sion (blood or crystalloid), the solution was delivered at 
37 ° C through a thermostatic oxygenator at a flow of 0.8 
ml- rain 1. gm 1. The perfusion pressure was monitored 
and was less than 40 mm Hg during the entire infusion 
period. In hearts protected with intermittent cold car- 
dioplegic infusion, the solution was infused at 20 ° C for 3 
minutes every 30 minutes. This moderate temperature was 
selected to circumvent the disadvantages and hazards of 
deep hypothermia while still retaining the benefits of 
moderate hypothermia. The temperature of the arrested 
hearts was continuously monitored with a thermistor 
probe placed into the right ventricular cavity through the 
pulmonary artery. Total preservation time for all hearts 
was 3 hours. 
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Group 
Control 
Continuous warm blood 
Continuous warm crystalloid 
Intermittent cold crystalloid 
n Preservation period Aerobic blood 
perfusion 
50 min 
6 
3h 
Assessment (n=6/group) of Assessment (n=6/group) of: 
Na+/K +-ATpase activity - contractile function 
- high energy phosphates 
Fig. 1. Experimental protocol. Control hearts (n = 6) were aerobically perfused with blood from support 
rat. Hearts (n = 12 per group) in continuous warm blood cardioplegic, continuous warm crystalloid 
cardioplegic, and intermittent cold cardioplegic groups were preserved for 3 hours with one of these three 
cardioplegic nterventions. At the end of this period, hearts (n = 6 per group) were taken for analysis of 
tissue Na--/K+-ATPase activity. Remaining hearts (n = 6 per group) were perfused aerobically with blood 
for additional 50 minutes and contractile function and high-energy phosphate l vels were assessed at the 
end of this period. 
Experimental protocol and study groups. Hearts (n = 
12 per group) were preserved for 3 hours with one of the 
following cardioplegic protocols: (1) continuous infusion 
of warm blood cardioplegic solution, (2) continuous infu- 
sion of warm crystalloid cardioplegic solution, or (3) 
intermittent infusion of cold St. Thomas' cardioplegic 
solution. At the end of this period, half of the hearts (n = 
6 per group) were taken for the determination of Na+/ 
K+-ATPase activity and the other half (n = 6 per group) 
were perfused aerobically in the Langendorff mode with 
blood from a support rat for 50 minutes at 37 ° C (Fig. 1). 
During this period, hearts were paced at 320 beats/min. 
For comparative purposes, hearts (n = 6) not receiving 
cardioplegic nfusion were aerobically perfused with blood 
for 50 minutes (Fig. 1). 
Metabolite analysis. At the end of the 50-minute per- 
fusion period, hearts were freeze-clamped, lyophilized, 
pulverized, and extracted in cold (4 ° C) 6% perchloric 
acid. Adenosine triphosphate (ATP) and creatine phos- 
phate (CP) contents were then determined by conven- 
tional spectrophotometric methods, 1° and the results were 
expressed micromoles per gram dry weight. 
Na+/K+-ATPase activity assay. At the end of 3 hours 
of preservation, ouabain-sensitive Na+/K+-ATPase activ- 
ity of left ventricular homogenates (n = 6 per group) was 
determined according to the method of Xie and cowork- 
ers 1~ by measuring the ouabain-sensitive release of inor- 
ganic phosphate (Pi) from the hydrolysis of ATP during a 
10-minute period. Briefly, approximately 100 mg of tissue 
was accurately weighed and homogenized in 1.0 ml 10 
mmol/L of tris(hydroxymethyl)aminomethane hydrochlo- 
ride buffer (pH 7.4 at 37 ° C) containing 1 mmol/L ethyl- 
enediaminetetraacetic acid. A 0.1 ml aliquot of the ho- 
mogenate was added to 0.8 ml reaction medium of the 
following composition: 50 mmol/L tris(hydroxymethyl) 
aminomethane hydrochloride, 5 mmol/L magnesium 
chloride, 100 mmol/L sodium chloride, 15 mmol/L potas- 
sium chloride, and 5 mmol/L sodium azide. After 5 
minutes of equilibration at 37 ° C, the reaction was initi- 
ated by the addition of 0.1 ml 50 mmol/L tris(hydroxy- 
methyl)aminomethane-ATP. he reaction was stopped 
after 10 minutes by the addition of 0.1 ml ice-cold i mol/L 
trichloroacetic acid, and the resulting protein precipitate 
was separated by centrifugation at 1200g for 3 minutes. 
The Pi content of the supernatant was determined accord- 
ing to Stanton. 12 Briefly, 140 /xl acid molybdate solution 
(0.01 mmol/L in 1.2 mol/L sulfuric acid) was added to 40 
/xl supernatant in each well of a 96-well microplate. A
further 40/xl Fiske and Subbarow reagent (Sigma Chem- 
ical Co., Poole, U.K.) was added, and after 10 rain 
incubation at room temperature, the absorbence of the 
contents of each well was measured at 600 nm by means of 
Bio-Tek Kineticalc software (Bio-Tek Instruments, Inc., 
Winsooski, Vt.) with 0.01 to 0.2 mmol/L potassium phos- 
phate as a standard for Pi. Ouabain-sensitive Na+/K +- 
ATPase activity was determined by substraction of the 
ATPase activity calculated in the presence of 1 mmol/L 
ouabain from the total ATPase activity determined in the 
absence of ouabain. Samples were incubated with ouabain 
for 15 minutes at 37°C before the determination of 
Na+/K+-ATPase activity. Na+/K+-ATPase activity was 
expressed as micromoles of Pi released per milligram of 
tissue per 10 minutes. Fresh rat hearts (n = 6) were used 
as control preparations. 
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Fig. 2. Systolic (A) and diastolic (B) functions at the end of 50 minutes of aerobic blood perfusion in 
control hearts (n = 6) and hearts (n = 6 per group) protected with continuous warm blood cardioplegic 
infusion, continuous warm crystalloid cardioplegic nfusion, and intermittent cold cardioplegic nfusion. 
Data presented as mean _+ SEM. Asterisk indicates p < 0.05 compared with intermittent cold cardioplegic 
and continuous warm crystalloid cardioplegic groups; dagger indicates p < 0.05 compared with all other 
groups; hatch mark indicates p < 0.05 compared with intermittent cold cardioplegic and control groups. 
Statistical analysis. All results were expressed as the 
mean (_+ standard error of the mean [SEM]). Analysis of 
variance was employed for multiple comparisons. When a 
significant F value was obtained, comparison between 
means was carried out with Tukey's test. A difference was 
considered statistically significant at p values less than 
0.05. 
Results 
Contractile function. Fig. 2 (A) shows that sys- 
tolic function at all balloon volumes had deterio- 
rated significantly by the end of the experimental 
period in all cardioplegic groups when compared 
with control hearts. Hearts protected with continu- 
ous warm blood cardioplegic infusion, however, 
tended to exhibit better function than those treated 
with continuous warm crystalloid or intermittent 
cold cardioplegic infusion, and this difference 
achieved statistical significance at balloon volumes 
of 150 to 240/~1. For example, at a balloon volume 
of 180/~1, the mean value for left ventricular devel- 
oped pressure was 122 _+ 5 mm Hg in control hearts, 
whereas left ventricular developed pressures in 
hearts perfused with continuous warm crystalloid or 
intermittent cold cardioplegic solution, were only 70 
-+ 5 and 78 _+ 5 mm Hg, respectively. In hearts 
perfused continuously with warm blood cardioplegic 
solution, the value was 98 +_ 5 mm Hg (p < 0.05). 
In contrast to the results for systolic function, 
diastolic function (Fig. 2, B) was significantly im- 
paired in hearts perfused with continuous warm 
blood and crystalloid cardioplegic solutions when 
compared with control hearts. Diastolic function 
was fully preserved, however, in hearts treated with 
intermittent cold cardioplegic infusion. For the ex- 
ample of 180/xl balloon volume, the mean values for 
left ventricular end-diastolic pressure in continuous 
warm blood and crystalloid cardioplegic groups 
were 33 + 3 and 32 _+ 6 mmHg, whereas the value 
in hearts protected with intermittent cold cardiople- 
gic infusion was 14 _+ 4 mm Hg, a value that did not 
differ significantly from that of controls hearts (16 _+ 
3 mm Hg). 
Coronary perfusion pressure. Fig. 3 shows the 
profile for coronary perfusion pressure during the 50 
minutes of aerobic blood perfusion in all groups. 
Because hearts were perfused at a constant flow 
rate, this index reflects changes in coronary vascular 
resistance. The profiles of coronary perfusion pres- 
sure were similar in all study groups. At the end of 
the 50-minute perfusion period, the mean values of 
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Fig. 3. Perfusion pressure during 50 minutes of aerobic 
blood perfusion in control hearts (n = 6) and hearts (n = 
6 per group) protected with continuous warm blood 
cardioplegic infusion, continuous warm crystalloid car- 
dioplegic infusion, and intermittent cold cardioplegic n- 
fusion. Data presented as mean -+ SEM. 
coronary perfusion pressure were 63 -+ 3, 68 + 2.6, 
and 59 + 4 mm Hg in the continuous warm blood 
cardioplegic infusion, crystalloid cardioplegic infu- 
sion, and intermittent cold cardioplegic infusion 
groups, respectively. The corresponding value in 
control hearts was 61 ± 3 mm Hg (p not significant). 
Tissue high-energy phosphate content. As shown 
in Fig. 4 (A), the tissue content of ATP in all 
cardioplegic groups was depleted by more than 50% 
(11.7 ± 1.2, 9.8 - 1.1, and 8.2 _+ 1.0 fLmol/gm dry 
weight in the continuous warm blood cardioplegic 
infusion, crystalloid cardioplegic infusion, and inter- 
mittent cold cardioplegic infusion groups, respec- 
tively) compared with the value obtained in aerobic 
control preparations (20.5 ± 1.2 /~mol/gm dry 
weight; p < 0.05 in all cases). The contents of CP 
(Fig. 4, B) were similar in all cardioplegic groups 
and in control hearts. 
Na+/K+-ATPase activity. As shown in Fig. 5, at 
the end of the experimental period hearts receiving 
continuous warm blood and intermittent cold car- 
dioplegic infusion had myocardial Na+/K+-ATPase 
activities (0.032 ± 0.015 and 0.031 ± 0.013 ~LmO1 
Pi" mg -1" rain -1, respectively) similar to that ob- 
served in control hearts perfused aerobically with 
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Fig. 4. Tissue ATP (A) and CP (B) levels at end of 50 
minutes of aerobic blood perfnsion in control hearts (n = 
6) and hearts (n = 6 per group) protected with continuous 
warm blood cardioplegic nfusion, continuous warm crys- 
talloid cardioplegic infusion, and intermittent cold car- 
dioplegic infusion. Data presented as mean + SEM. 
Asterisk indicates p < 0.05 compared with control hearts. 
blood for 50 minutes (0.30 -+ 0.008 /xmol 
Pi. mg -1.  min -1, p not significant). Hearts receiv- 
ing continuous warm crystalloid cardioplegic infu- 
sion, however, exhibited significantly decreased 
Na+/K+-ATPase activity (0.012 ± 0.003 /xmol 
Pi. mg -1.  min-1; p < 0.05) compared with control 
hearts and with hearts treated with continuous warm 
blood and intermittent cold cardioplegic infusions. 
Discussion 
The results of this study with the blood-perfused 
rat heart indicate that although none of the three 
interventions tudied conferred full protection of 
contractile function, (1) systolic function was best 
preserved with continuous warm blood cardioplegic 
infusion, whereas diastolic function was best pro- 
tected with intermittent cold crystalloid cardioplegic 
infusion; (2) vascular resistance was maintained 
within control values with each of the interventions; 
(3) tissue ATP content was equally depressed in all 
cases; and (4) Na+/K+-ATPase activity was unaf- 
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fected by either the temperature of the cardioplegic 
solution or the use of continuous versus intermittent 
infusion. Na+/K÷-ATPase activity was significantly 
depressed when blood was replaced by a crystalloid 
solution during continuous warm cardioplegic infu- 
sion. 
Continuous versus intermittent eardioplegic ad- 
ministration. Recently, continuous warm blood 
cardioplegic infusion has been proposed as a means 
of avoiding the risk of deleterious consequences of 
ischemia nd the detrimental effects of hypothermia 
associated with conventional cardioplegic proce- 
dures. Initial clinical results have been promising, 
and continuous warm cardioplegic nfusion has been 
adopted for use by a significant number of cardiac 
surgeons. It has been reported, however, that pa- 
tients protected with continuous warm blood car- 
dioplegic infusion have a higher prevalence of neu- 
rologic events and perioperative strokes, 8 greater 
prevalence of hyperkalemia, 13 and greater activation 
of neutrophils, t4 There is currently no conclusive 
evidence for the superiority of continuous warm 
cardioplegic infusion. 15 Furthermore, no experi- 
mental animal data support he superiority of con- 
tinuous warm blood cardioplegic infusion with re- 
spect to the more widely used intermittent cold 
cardioplegic infusion. This study is the first to com- 
pare the protective ffects of the two procedures in 
a controlled experimental setting. We have shown 
that neither continuous warm blood nor intermit- 
tent cold crystalloid cardioplegic infusion is able to 
afford full protection against he loss of contractile 
function and high-energy phosphates that occurs 
when hearts are subjected to a long period (3 hours) 
of cardiac arrest with no coronary flow or low 
coronary flow. We have also demonstrated that 
neither procedure appears consistently superior 
when other indexes of protection are used. Al- 
though continuous warm blood cardioplegic infu- 
sion appears to afford better protection when sys- 
tolic function is the end point, intermittent cold 
cardioplegic infusion appears to be superior when 
diastolic function is the end point. When high- 
energy phosphate levels are used as the end point, 
the procedures appear identical. 
An unexpected finding in this study was the 
reduction in ATP content that was detected in 
hearts that were protected with continuous warm 
cardioplegic infusion. This occurred despite car- 
dioplegic protection and the provision of a residual 
coronary flow rate that has been shown to be more 
than sufficient to meet the global oxygen demand of 
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Fig. 5. Tissue Na+/K+-ATPase activity in fresh control 
hearts (n = 6) and hearts (n = 6 per group) at the end of 
3 hours of protection with continuous warm blood car- 
dioplegic infusion, continuous warm crystalloid cardiople- 
gic infusion, and intermittent cold cardioplegic infusion. 
Data presented as mean _+ SEM. Asterisk indicates p < 
0.05 compared with all other groups. 
the arrested heart. 16' iv One possible xplanation for 
this finding could be the heterogeneous redistribu- 
tion of low levels of flow resulting in hypoperfusion 
(and thus ischemia) in some regions of the heart. 
This possibility is supported by reports is of ultra- 
structural damage and the existence of areas without 
reflow in human hearts been protected with contin- 
uous blood cardioplegic infusion. If this heteroge- 
neous redistribution of flow is confirmed, the prob- 
lem may be particularly relevant in the presence of 
myocardial hypertrophy or severe coronary artery 
stenosis. If such were to prove the case, then the 
recommended flow rate for continuous warm car- 
dioplegic infusion might need to be increased. Such 
a change could, however, create impractical opera- 
tive conditions. It is interesting to note that a low 
perfusion pressure during continuous infusion of 
warm cardioplegic solution, as occurred in our 
study, may aggravate any existing heterogenous re- 
distribution of flow. Adequacy of flow rate, ade- 
quacy of perfusion pressure, and their relationship 
clearly need further investigation. 
The temperature of cardioplegic solution. The 
disadvantages and hazards of hypothermia are well 
known, but they are far outweighed by the advan- 
tages when used as an adjunct o cardioplegic infu- 
sion. 1 A major contributor to hypothermia-induced 
cellular injury is ionic redistribution and cell swell- 
ing. A key mechanism responsible for cold swelling 
is thought to be inactivation by hypothermia of 
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sarcolemmal Na+/K+-ATPase, a condition that 
would tend to exacerbate intracellular sodium over- 
loading and (where ischemia and reperfusion are 
involved) predispose toward calcium overloading 
during reperfusion. In contrast o what might be 
expected, however, Na+/K+-ATPase activity was 
normal in the crystalloid cardioplegic group. 
Deterioration of diastolic function after open- 
chest operations has been reported. ~9 One surpris- 
ing finding of our study was that diastolic function 
was better preserved in the cold intermittent car- 
dioplegic group than in the continuous normother- 
mic blood cardioplegic group. Furthermore, the 
coronary vascular esistance in hearts that had been 
subjected to hypothermia was similar to that of 
control hearts and hearts protected with continuous 
warm cardioplegic infusion. These results suggest 
that hypothermia, despite the changes induced in 
the physical properties of the various cell elements, 
may not adversely alter the lusitropic properties of 
the contractile apparatus or the integrity of the 
vasculature. Our results suggest that moderate 
(20 ° C) hypothermia may in itself have no detrimen- 
tal effects when used as an adjunct o intermittent 
cardioplegic infusion. 
Importance of blood components in continuous 
cardioplegic infusion. Although it is natural to as- 
sume that blood would be the best vehicle for the 
delivery of continuous warm cardioplegic protec- 
tion, its use may not be without hazard. The expo- 
sure of blood to foreign surfaces (necessary in the 
preparation and administration of a blood car- 
dioplegic solution) may promote the formation of 
microaggregates and activation of neutrophils, both 
of which could negatively influence the ability of 
blood cardioplegic solutions to preserve tissue via- 
bility. On the basis of this consideration, it could be 
argued that crystalloid cardioplegic solutions offer 
better protection than blood-based solutions when 
used in a continuous-infusion mode. This study has 
shown, however, that continuous warm cardioplegic 
infusion of a crystalloid solution is not as effective as 
continuous warm infusion of blood in preserving 
systolic function. This difference was not related to 
tissue content of high-energy phosphates, because 
tissue ATP and CP levels were similar in both cases. 
The loss of contractile function with continuous 
crystalloid cardioplegic infusion could, however, be 
related to the apparent loss of Na+/K+-ATPase 
activity observed at the end of the preservation 
period in hearts protected with continuous warm 
crystalloid cardioplegic infusion. Such a loss of 
Na+/K+-ATPase activity may have adverse effects 
on intracellular sodium and calcium homeostasis 
and thus may adversely affect contractile activity. 
Clinical implications and future directions. Con- 
tinuous warm blood cardioplegic infusion has been 
adopted for routine use by a substantial number of 
cardiac surgeons. It has been suggested that this 
procedure offers a greater margin of safety than 
other forms of myocardial protection, despite the 
absence of rigorous surgical trials and the lack of 
detailed experimental studies upporting its superi- 
ority. Although limited by the use of the blood- 
perfused rat heart, this study draws attention to the 
fact that warm continuous blood cardioplegic infu- 
sion may appear better than, worse than, or similar 
to intermittent, cold cardioplegic infusion, depend- 
ing on the indexes used for assessment. Clearly more 
work is required to resolve this controversy; as 
illustrated by this study, future investigations should 
consider the dangers of employing asingle end point 
in the assessment of injury and protection. 
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